<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31558719</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound.</ArticleTitle><Pagination><StartPage>4373</StartPage><MedlinePgn>4373</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4373</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-019-12426-9</ELocationID><Abstract><AbstractText>MR-guided focused ultrasound (MRgFUS) is an emerging technology that can accurately and transiently permeabilize the blood-brain barrier (BBB) for targeted drug delivery to the central nervous system. We conducted a single-arm, first-in-human trial to investigate the safety and feasibility of MRgFUS-induced BBB opening in eloquent primary motor cortex in four volunteers with amyotrophic lateral sclerosis (ALS). Here, we show successful BBB opening using MRgFUS as demonstrated by gadolinium leakage at the target site immediately after sonication in all subjects, which normalized 24&#x2009;hours later. The procedure was well-tolerated with no serious clinical, radiologic or electroencephalographic adverse events. This study demonstrates that non-invasive BBB permeabilization over the motor cortex using MRgFUS is safe, feasible, and reversible in ALS subjects. In future, MRgFUS can be coupled with promising therapeutics providing a targeted delivery platform in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abrahao</LastName><ForeName>Agessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1142-2842</Identifier><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada. agessandro.abrahao@sunnybrook.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada. agessandro.abrahao@sunnybrook.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, ON, M4N 3M5, Canada. agessandro.abrahao@sunnybrook.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llinas</LastName><ForeName>Maheleth</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuexi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamani</LastName><ForeName>Clement</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mainprize</LastName><ForeName>Todd</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aubert</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-5163-9961</Identifier><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, M5S 3H7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heyn</LastName><ForeName>Chinthaka</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Odette Cancer Research, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0001-7093-8289</Identifier><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, M5S 3H7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hynynen</LastName><ForeName>Kullervo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Odette Cancer Research, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, M5S 3H7, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biophysics, University of Toronto, Toronto, ON, M5S 3H7, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipsman</LastName><ForeName>Nir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harquail Centre for Neuromodulation, Sunnybrook Research Institute, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, M4N 3M5, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018686">Anesthetics, Intravenous</NameOfSubstance></Chemical><Chemical><RegistryNumber>R60L0SM5BC</RegistryNumber><NameOfSubstance UI="D008874">Midazolam</NameOfSubstance></Chemical><Chemical><RegistryNumber>UF599785JZ</RegistryNumber><NameOfSubstance UI="D005283">Fentanyl</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018686" MajorTopicYN="N">Anesthetics, Intravenous</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005283" MajorTopicYN="N">Fentanyl</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008874" MajorTopicYN="N">Midazolam</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>N.L., K.H., and S.E.B. have received an honorarium from the Focused Ultrasound Foundation for serving on an expert steering committee on focused ultrasound in Alzheimer&#x2019;s Disease. K.H. is an inventor on intellectual property owned by Brigham and Women&#x2019;s hospital in Boston and Sunnybrook Research Institute in Toronto related to intracranial focused ultrasound technology. A.A., Y.M., M.L., C.Hamani, Y.H., T.M., I.A., C.Heyn, N.L., and L.Z. declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31558719</ArticleId><ArticleId IdType="pmc">PMC6763482</ArticleId><ArticleId IdType="doi">10.1038/s41467-019-12426-9</ArticleId><ArticleId IdType="pii">10.1038/s41467-019-12426-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dadon-Nachum M, Melamed E, Offen D. The &#x2018;dying-back&#x2019; phenomenon of motor neurons in ALS. J. Mol. Neurosci. MN. 2011;43:470&#x2013;477. doi: 10.1007/s12031-010-9467-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9467-1</ArticleId><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, et al. Cortical influences drive amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2017;88:917&#x2013;924. doi: 10.1136/jnnp-2017-315573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315573</ArticleId><ArticleId IdType="pubmed">28710326</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, et al. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J. Neurosci. 2014;34:15587&#x2013;15600. doi: 10.1523/JNEUROSCI.2037-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2037-14.2014</ArticleId><ArticleId IdType="pmc">PMC4298650</ArticleId><ArticleId IdType="pubmed">25411487</ArticleId></ArticleIdList></Reference><Reference><Citation>Handley EE, et al. Synapse dysfunction of layer V pyramidal neurons precedes neurodegeneration in a mouse model of TDP-43 proteinopathies. Cereb. Cortex. 2017;27:3630&#x2013;3647.</Citation><ArticleIdList><ArticleId IdType="pubmed">27496536</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng M-C, et al. Abnormal diffusion tensor in nonsymptomatic familial amyotrophic lateral sclerosis with a causative superoxide dismutase 1 mutation. J. Magn. Reson. Imaging. 2007;27:8&#x2013;13. doi: 10.1002/jmri.21217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmri.21217</ArticleId><ArticleId IdType="pubmed">18022844</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Kiernan MC, Vucic S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clin. Neurophysiol. 2015;126:803&#x2013;809. doi: 10.1016/j.clinph.2014.04.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2014.04.023</ArticleId><ArticleId IdType="pubmed">25227219</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, et al. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007;1157:126&#x2013;137. doi: 10.1016/j.brainres.2007.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.04.044</ArticleId><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Sanberg PR. Blood-CNS barrier impairment in ALS patients versus an animal model. Front Cell Neurosci. 2014;8:21. doi: 10.3389/fncel.2014.00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00021</ArticleId><ArticleId IdType="pmc">PMC3910123</ArticleId><ArticleId IdType="pubmed">24550780</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson A, et al. Potential new complication in drug therapy development for amyotrophic lateral sclerosis. Expert Rev. Neurother. 2016;16:1397&#x2013;1405. doi: 10.1080/14737175.2016.1207530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2016.1207530</ArticleId><ArticleId IdType="pmc">PMC5164916</ArticleId><ArticleId IdType="pubmed">27362330</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski MR, et al. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Ann. Clin. Transl. Neurol. 2014;1:996&#x2013;1005. doi: 10.1002/acn3.141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.141</ArticleId><ArticleId IdType="pmc">PMC4284125</ArticleId><ArticleId IdType="pubmed">25574474</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, et al. Transplantation of neural progenitor cells expressing glial cell line-derived neurotrophic factor into the motor cortex as a strategy to treat amyotrophic lateral sclerosis. Stem Cells. 2018;36:1122&#x2013;1131. doi: 10.1002/stem.2825.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2825</ArticleId><ArticleId IdType="pubmed">29656478</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez HR, et al. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy. 2009;11:26&#x2013;34. doi: 10.1080/14653240802644651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14653240802644651</ArticleId><ArticleId IdType="pubmed">19191058</ArticleId></ArticleIdList></Reference><Reference><Citation>Boado RJ, Hui EK-W, Lu JZ, Zhou Q-H, Pardridge WM. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous trojan horse-iduronidase fusion protein. Mol. Pharm. 2011;8:1342&#x2013;1350. doi: 10.1021/mp200136x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/mp200136x</ArticleId><ArticleId IdType="pubmed">21667973</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsman N, et al. Blood-brain barrier opening in Alzheimer&#x2019;s disease using MR-guided focused ultrasound. Nat. Commun. 2018;9:2336. doi: 10.1038/s41467-018-04529-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-04529-6</ArticleId><ArticleId IdType="pmc">PMC6060168</ArticleId><ArticleId IdType="pubmed">30046032</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynynen K, Jolesz FA. Demonstration of potential noninvasive ultrasound brain therapy through an intact skull. Ultrasound Med. Biol. 1998;24:275&#x2013;283. doi: 10.1016/S0301-5629(97)00269-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0301-5629(97)00269-X</ArticleId><ArticleId IdType="pubmed">9550186</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias WJ, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N. Engl. J. Med. 2016;375:730&#x2013;739. doi: 10.1056/NEJMoa1600159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1600159</ArticleId><ArticleId IdType="pubmed">27557301</ArticleId></ArticleIdList></Reference><Reference><Citation>Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA, Noninvasive MR. imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001;220:640&#x2013;646. doi: 10.1148/radiol.2202001804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2202001804</ArticleId><ArticleId IdType="pubmed">11526261</ArticleId></ArticleIdList></Reference><Reference><Citation>McDannold N, Vykhodtseva N, Raymond S, Jolesz FA, Hynynen K. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med. Biol. 2005;31:1527&#x2013;1537. doi: 10.1016/j.ultrasmedbio.2005.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ultrasmedbio.2005.07.010</ArticleId><ArticleId IdType="pubmed">16286030</ArticleId></ArticleIdList></Reference><Reference><Citation>McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res. 2012;72:3652&#x2013;3663. doi: 10.1158/0008-5472.CAN-12-0128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-12-0128</ArticleId><ArticleId IdType="pmc">PMC3533365</ArticleId><ArticleId IdType="pubmed">22552291</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe3;o JF, et al. Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer&#x2019;s disease. PLoS One. 2010;5:e10549. doi: 10.1371/journal.pone.0010549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010549</ArticleId><ArticleId IdType="pmc">PMC2868024</ArticleId><ArticleId IdType="pubmed">20485502</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;venot E, et al. Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound. Hum. Gene Ther. 2012;23:1144&#x2013;1155. doi: 10.1089/hum.2012.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2012.013</ArticleId><ArticleId IdType="pmc">PMC3498907</ArticleId><ArticleId IdType="pubmed">22838844</ArticleId></ArticleIdList></Reference><Reference><Citation>Noroozian Z, et al. MRI-guided focused ultrasound for targeted delivery of raav to the brain. Methods Mol. Biol. 2019;1950:177&#x2013;197. doi: 10.1007/978-1-4939-9139-6_10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9139-6_10</ArticleId><ArticleId IdType="pmc">PMC6546162</ArticleId><ArticleId IdType="pubmed">30783974</ArticleId></ArticleIdList></Reference><Reference><Citation>Alli S, et al. Brainstem blood brain barrier disruption using focused ultrasound: a demonstration of feasibility and enhanced doxorubicin delivery. J. Control Release. 2018;281:29&#x2013;41. doi: 10.1016/j.jconrel.2018.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2018.05.005</ArticleId><ArticleId IdType="pmc">PMC6026028</ArticleId><ArticleId IdType="pubmed">29753957</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpentier A, et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci. Transl. Med. 2016;8:343re2. doi: 10.1126/scitranslmed.aaf6086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6086</ArticleId><ArticleId IdType="pubmed">27306666</ArticleId></ArticleIdList></Reference><Reference><Citation>Idbaih Ahmed, Canney Michael, Belin Lisa, Desseaux Carole, Vignot Alexandre, Bouchoux Guillaume, Asquier Nicolas, Law-Ye Bruno, Leclercq Delphine, Bissery Anne, De Rycke Yann, Trosch Clementine, Capelle Laurent, Sanson Marc, Hoang-Xuan Khe, Dehais Caroline, Houillier Caroline, Laigle-Donadey Florence, Mathon Bertrand, Andr&#xe9; Arthur, Lafon Cyril, Chapelon Jean-Yves, Delattre Jean-Yves, Carpentier Alexandre. Safety and Feasibility of Repeated and Transient Blood&#x2013;Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma. Clinical Cancer Research. 2019;25(13):3793&#x2013;3801. doi: 10.1158/1078-0432.CCR-18-3643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-18-3643</ArticleId><ArticleId IdType="pubmed">30890548</ArticleId></ArticleIdList></Reference><Reference><Citation>Mainprize T, et al. Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused. Ultrasound.: A Clin. Saf. Feasibility Study Sci. Rep. 2019;9:321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6344541</ArticleId><ArticleId IdType="pubmed">30674905</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Alkins R, Schwartz ML, Hynynen K. Opening the blood-brain barrier with MR imaging-guided focused ultrasound: preclinical testing on a trans-human skull porcine model. Radiology. 2017;282:123&#x2013;130. doi: 10.1148/radiol.2016152154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2016152154</ArticleId><ArticleId IdType="pmc">PMC5179309</ArticleId><ArticleId IdType="pubmed">27420647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs ZI, et al. Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation. Proc. Natl Acad. Sci. USA. 2017;114:E75&#x2013;E84. doi: 10.1073/pnas.1614777114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1614777114</ArticleId><ArticleId IdType="pmc">PMC5224365</ArticleId><ArticleId IdType="pubmed">27994152</ArticleId></ArticleIdList></Reference><Reference><Citation>Silburt J, Lipsman N, Aubert I. Disrupting the blood&#x2013;brain barrier with focused ultrasound: Perspectives on inflammation and regeneration. Proc. Natl Acad. Sci. USA. 2017;114:E6735&#x2013;E6736. doi: 10.1073/pnas.1710761114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1710761114</ArticleId><ArticleId IdType="pmc">PMC5565470</ArticleId><ArticleId IdType="pubmed">28798067</ArticleId></ArticleIdList></Reference><Reference><Citation>Coluccia D, et al. Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound. Nanomed. 2018;14:1137&#x2013;1148. doi: 10.1016/j.nano.2018.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2018.01.021</ArticleId><ArticleId IdType="pubmed">29471172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobus T, Zervantonakis IK, Zhang Y, McDannold NJ. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption. J. Control. Release . J. Control. Release Soc. 2016;238:281&#x2013;288. doi: 10.1016/j.jconrel.2016.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2016.08.001</ArticleId><ArticleId IdType="pmc">PMC5014601</ArticleId><ArticleId IdType="pubmed">27496633</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H-L, et al. Focused ultrasound enhances central nervous system delivery of bevacizumab for malignant glioma treatment. Radiology. 2016;281:99&#x2013;108. doi: 10.1148/radiol.2016152444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2016152444</ArticleId><ArticleId IdType="pubmed">27192459</ArticleId></ArticleIdList></Reference><Reference><Citation>Alecou T, Giannakou M, Damianou C. Amyloid &#x3b2; plaque reduction with antibodies crossing the blood-brain barrier, which was opened in 3 sessions of focused ultrasound in a rabbit model. J. Ultrasound Med. 2017;36:2257&#x2013;2270. doi: 10.1002/jum.14256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jum.14256</ArticleId><ArticleId IdType="pubmed">28543446</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess A, et al. Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood-brain barrier. PLoS One. 2011;6:e27877. doi: 10.1371/journal.pone.0027877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0027877</ArticleId><ArticleId IdType="pmc">PMC3218061</ArticleId><ArticleId IdType="pubmed">22114718</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkins R, et al. Focused ultrasound delivers targeted immune cells to metastatic brain tumors. Cancer Res. 2013;73:1892&#x2013;1899. doi: 10.1158/0008-5472.CAN-12-2609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-12-2609</ArticleId><ArticleId IdType="pmc">PMC3607446</ArticleId><ArticleId IdType="pubmed">23302230</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkins R, Burgess A, Kerbel R, Wels WS, Hynynen K. Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. Neuro-Oncol. 2016;18:974&#x2013;981. doi: 10.1093/neuonc/nov318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/neuonc/nov318</ArticleId><ArticleId IdType="pmc">PMC4896543</ArticleId><ArticleId IdType="pubmed">26819443</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisbet RM, et al. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Brain J. Neurol. 2017;140:1220&#x2013;1230. doi: 10.1093/brain/awx052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx052</ArticleId><ArticleId IdType="pmc">PMC5405237</ArticleId><ArticleId IdType="pubmed">28379300</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Ezzi SA, Julien J-P. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl Acad. Sci. USA. 2007;104:2495&#x2013;2500. doi: 10.1073/pnas.0606201104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0606201104</ArticleId><ArticleId IdType="pmc">PMC1790867</ArticleId><ArticleId IdType="pubmed">17277077</ArticleId></ArticleIdList></Reference><Reference><Citation>Gros-Louis F, Soucy G, Lariviere R, Julien J-P. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. J. Neurochem. 2010;113:1188&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pubmed">20345765</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L, et al. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann. Neurol. 2016;79:687&#x2013;700. doi: 10.1002/ana.24618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24618</ArticleId><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum. Mol. Genet. 2014;23:668&#x2013;681. doi: 10.1093/hmg/ddt454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt454</ArticleId><ArticleId IdType="pmc">PMC3888258</ArticleId><ArticleId IdType="pubmed">24108104</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber-Adrian D, et al. Gene delivery to the spinal cord using MRI-guided focused ultrasound. Gene Ther. 2015;22:568&#x2013;577. doi: 10.1038/gt.2015.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2015.25</ArticleId><ArticleId IdType="pmc">PMC4490035</ArticleId><ArticleId IdType="pubmed">25781651</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne AH, et al. Magnetic resonance imaging-guided focused ultrasound to increase localized blood-spinal cord barrier permeability. Neural Regen. Res. 2017;12:2045&#x2013;2049. doi: 10.4103/1673-5374.221162.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.221162</ArticleId><ArticleId IdType="pmc">PMC5784353</ArticleId><ArticleId IdType="pubmed">29323044</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly MA, et al. Preliminary investigation of focused ultrasound-facilitated drug delivery for the treatment of leptomeningeal metastases. Sci. Rep. 2018;8:9013. doi: 10.1038/s41598-018-27335-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-27335-y</ArticleId><ArticleId IdType="pmc">PMC5998139</ArticleId><ArticleId IdType="pubmed">29899537</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher SP, O&#x2019;Reilly MA. Analysis of multifrequency and phase keying strategies for focusing ultrasound to the human vertebral canal. IEEE Trans. Ultrason. Ferroelectr. Freq. Control. 2018;65:2322&#x2013;2331. doi: 10.1109/TUFFC.2018.2872171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TUFFC.2018.2872171</ArticleId><ArticleId IdType="pmc">PMC6309482</ArticleId><ArticleId IdType="pubmed">30273151</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Reilly MA, et al. Investigation of the safety of focused ultrasound-induced blood-brain barrier opening in a natural canine model of aging. Theranostics. 2017;7:3573&#x2013;3584. doi: 10.7150/thno.20621.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.20621</ArticleId><ArticleId IdType="pmc">PMC5596444</ArticleId><ArticleId IdType="pubmed">28912896</ArticleId></ArticleIdList></Reference><Reference><Citation>Konrad C, et al. Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Exp. Brain Res. 2002;143:51&#x2013;56. doi: 10.1007/s00221-001-0981-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00221-001-0981-9</ArticleId><ArticleId IdType="pubmed">11907690</ArticleId></ArticleIdList></Reference><Reference><Citation>Lule D, et al. Cortical plasticity in amyotrophic lateral sclerosis: motor imagery and function. Neurorehabil. Neural Repair. 2007;21:518&#x2013;526. doi: 10.1177/1545968307300698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1545968307300698</ArticleId><ArticleId IdType="pubmed">17476000</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanton BR, et al. Altered cortical activation during a motor task in ALS. Evidence for involvement of central pathways. J. Neurol. 2007;254:1260&#x2013;1267. doi: 10.1007/s00415-006-0513-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0513-4</ArticleId><ArticleId IdType="pubmed">17385077</ArticleId></ArticleIdList></Reference><Reference><Citation>Jord&#xe3;o JF, et al. Amyloid-&#x3b2; plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound. Exp. Neurol. 2013;248:16&#x2013;29. doi: 10.1016/j.expneurol.2013.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2013.05.008</ArticleId><ArticleId IdType="pmc">PMC4000699</ArticleId><ArticleId IdType="pubmed">23707300</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr. Opin. Neurol. 2018;31:635&#x2013;639. doi: 10.1097/WCO.0000000000000599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht DS, Granziera C, Hooker JM, Loggia ML. In vivo imaging of human neuroinflammation. ACS Chem. Neurosci. 2016;7:470&#x2013;483. doi: 10.1021/acschemneuro.6b00056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.6b00056</ArticleId><ArticleId IdType="pmc">PMC5433433</ArticleId><ArticleId IdType="pubmed">26985861</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, et al. Excellent inter&#x2010;rater, intra&#x2010;rater, and telephone&#x2010;administered reliability of the ALSFRS&#x2010;R in a multicenter clinical trial. Amyotroph. Lateral Scler. 2007;8:42&#x2013;46. doi: 10.1080/17482960600888156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600888156</ArticleId><ArticleId IdType="pubmed">17364435</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage. 2012;61:1402&#x2013;1418. doi: 10.1016/j.neuroimage.2012.02.084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.02.084</ArticleId><ArticleId IdType="pmc">PMC3389460</ArticleId><ArticleId IdType="pubmed">22430496</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>